We have studied the genomic organization of the c-myc locus (MYC) from 121 human primary breast carcinomas. Two types of alterations were observed: (i) the c-myc protooncogene appeared to be amplified 2-to 15-fold in 38 (32%) of the carcinoma DNAs and (ii) a non-germ-line c-myc-related fragment of variable size was detected in 5 primary breast carcinoma DNAs. With three exceptions, all the tumors containing a genetic alteration of the c-myc locus were invasive ductal carcinomas. A significant correlation (P < 0.02) was observed between patients more than 50 years old and the presence of a genetically altered c-myc. Enhanced levels of c-myc RNA were observed in 10 of 14 breast carcinomas examined. The c-myc gene was genetically altered in 6 of these 10 tumors. The frequency with which the c-myc gene is altered and its correlation with age suggest that it may play a role in the development of breast carcinomas.
Human breast cancer is a complex of neoplastic diseases that vary in histological appearance and biological behavior such as potential for invasiveness and metastasis (1). Several epigenetic factors may influence the development of malignant breast tumors, including hormonal status, age of the patient, frequency of successful pregnancies, and presence of hormone receptors on the tumor cells (2) . In addition, certain families have a high incidence of breast cancer, which suggests an inherited predisposition to breast tumor development (3) . At present, however, little information is available on the nature of the genetic changes that contribute to the development or progression of primary breast carcinomas.
Activated protooncogenes are believed to play an important role in tumor formation and/or progression (4) . Activation of c-myc expression by genetic rearrangement or amplification has been demonstrated in tissue culture cell lines derived from Burkitt lymphomas (5, 6) , promyelocytic leukemias (7, 8) , and colon (9) and lung (10) carcinomas. These genetic alterations of c-myc have been implicated as a contributing factor in the development of the respective malignancies. One of five breast cancer cell lines studied was found to have an amplified c-myc protooncogene (11) . In another study, high levels of c-myc RNA were observed in all four primary breast carcinomas examined (12) . In this report, we present an analysis of the c-myc protooncogene in 121 surgical samples of human primary breast carcinomas. Our objective was to determine whether the c-myc locus was genetically altered in these carcinomas and how this correlates with the level of c-myc RNA and the clinicopathological data. We found variable levels of amplification of the c-myc protooncogene in 32% of the carcinomas tested. In addition, we found a rearranged c-myc protooncogene in five primary carcinomas. In one of them the breakpoint was located at the 3' end of the c-myc gene. High levels of expression of c-myc were detected when the locus was amplified. However, elevated levels of c-myc RNA were also observed in some tumors where the c-myc gene was unaltered. The genetic alteration of the c-myc protooncogene is significantly linked (P < 0.02) to patients older than 50 years, which suggests that activation of c-myc might be an important factor in the development and/or the progression of some human breast carcinomas. (19) and the f8-actin (20) probes used in this study were generously given by, respectively, A. Nienhuis (National Heart, Lung and Blood Institute) and J. Fetherston (University of Kentucky). The (11) . The recombinant DNAs used as probes were nick-translated as described (16) .
MATERIAL AND METHODS
Hybridization Conditions. After transfer of the nucleic acids, nylon membranes were rinsed in 6x SSC (lx SSC is 0.15 M NaCl/0.015 M sodium citrate, pH 7.0) and baked for 2 hr at 80'C. Prehybridizations were carried out at 370C for at least 2 hr in 50%6 (vol/vol) formamide/0.1% Ficoll/0.1% polyvinylpyrrolidone/0.1% bovine serum albumin/1% NaDodSO4/0.45 M NaCl/0.03 M sodium phosphate, pH 7.4/1 mM EDTA/2.5% dextran sulfate/i mM sodium pyrophosphate, pH 6.5. For hybridization, the nylon membranes were then incubated for 48 hr at 370C in heat-sealed plastic bags with hybridization solution (identical to prehybridization solution) containing 3 x 106 cpm of 32P-labeled plasmid DNA per ml. Unbound probe was removed from the membranes by washing once at room temperature with 3 x SSC/0.5% NaDodSO4 and three times (15 min each) at 65°C with 0.1 x SSC/0.5% NaDodSO4. The membranes were then exposed for autoradiography.
Measurement of c-myc Amplification. Restriction enzymedigested tumor DNAs were compared with matching lymphocyte DNA in the same agarose gels. In cases where the matching lymphocyte DNAs were unavailable, digested tumor DNAs were compared with a standard normal lymphocyte DNA in the same gel. Blots of these gels were first hybridized with the c-myc probe. After autoradiography, hybridized probe was removed by washing for 30 min in 0.4 M NaOH, and the blots were neutralized in 0.1 x SSC/0.2 M Tris, pH 7.5/0.5% NaDodSO4 for 1 hr at 42°C and then rehybridized with the f3-globin probe. Densitometric measurements of the c-myc and 3-globin autoradiographs were made for each lane of the gel. To minimize the effect of variability in the amount of DNA in each lane, the areas under the ,3-globin curves were normalized to a standard lymphocyte DNA analyzed in the same gel. These values were used to correct the area under each c-myc curve on the same gel. The level of amplification was determined by comparing the corrected c-myc area in the tumor DNA with that of the lymphocyte DNA.
RESULTS
c-myc Protooncogene Alterations in Human Primary Breast Cancers. Samples from 121 primary breast carcinomas and 5 fibroadenomas were examined for genetic alteration of the c-myc protooncogene. Different types of alterations were observed in 43 (36%) of the HindIII-digested carcinoma DNAs. The most frequent type was the amplification of c-myc, seen in 38 (32%) of the tumor DNAs ( Fig. 1 A, lanes c-g, and B,lanes b, d, f, and h). Peripheral lymphocyte DNAs from 45 patients were used as a reference for measuring the extent of amplification. In addition, the 3-globin gene was used as an internal control for the amount ofDNA transferred to the filters. The level of amplification was estimated by densitometric tracing of the 11.5-kilobase (kb) c-myc and the 8.2-kb globin-gene fragments of the tumor and lymphocyte DNAs. By using this criterion, we observed low levels of amplification of c-myc (2-to 5-fold) in 25 (21%) carcinoma DNAs ( Fig. 1 A, lanes c and d, and B, lanes b and d). In the other 13 (11%) tumor DNAs, the intensity of the c-myc hybridization was 6-15 times that observed in normal lymphocyte DNAs (Fig. 1 A, lanes e-g, and B, lanes f and h) . The c-mos protooncogene is also located on human chromosome 8 . Using a similar approach, we have found no evidence for the amplification of c-mos in the tumor DNAs described here (ref. 21 and data not shown). The distribution of a genetically altered c-myc locus among the different histological types of carcinomas examined (Table 1) showed that, with the exception of one in situ lobular and one spindle-cell carcinoma, all tumor DNAs bearing an amplification of the c-myc protooncogene were invasive ductal carcinomas. Thus, 38% of the invasive ductal carcinomas of the breast examined in this study have an amplified c-myc domain.
The second type of alteration detected with the pRyc7.4 c-myc probe was the presence of a novel c-myc-related HindIII fragment in 5 (4%) carcinomas (4 invasive ductal and 1 mucinous) (Fig. 1 A, lanes h and i, Genetics: Escot et al.
non-germ-line c-myc-related fragments ranged in size between 4 and 8 kb. We conclude that they probably represent rearrangements of the c-myc locus, since no HindIII restriction site polymorphism has been reported to date or observed in this study. In addition, the rearranged fragment in one tumor (no. 290) was not observed in DNA from peripheral lymphocytes of the patient (Fig. 1B, compare lanes i and j) . We have further characterized the rearranged c-myc locus in DNA of tumor 290 by restriction enzyme analysis. Blots of tumor-290 DNA that had been restricted with HindIII, EcoRI, and Pvu II were hybridized with probes (Fig. 2 Lower) corresponding to exon I (probe a), exons II and III (probe b), exon III and 3' flanking cellular sequences (probe c), and exon II (probe d). In HindIII-digested DNA, all of the probes detected a rearranged 8.0-kb fragment (Fig. 2 A-D,  lanes a) . In addition, probe c detected a non-germ-line 5.8-kb fragment (Fig. 2C, lane a) . All four probes detected a non-germ-line 18-kb EcoRI fragment (Fig. 2 A-D, lanes b) . In the case of probe c, this probably obscured the predicted 18-kb germ-line fragment corresponding to sequences located 3' of the c-myc gene. These results suggest that the genetic alteration occurred between the 5' HindIII and 3' EcoRI sites ofthe c-myc locus. The genetic alteration was further defined and localized by analysis of Pvu II-digested DNA. Probes a and d detected only germ-line fragments ( Fig. 2 A and D , lanes c), whereas probes b and c each hybridized to a novel 6.8-kb fragment (Fig. 2 D and C, (Fig. 2C, lanes a and c) .
Enhanced c-myc protooncogene was measured by blot-hybridization analysis of electrophoretically fractionated poly(A)+ RNA from 14 invasive ductal carcinomas, among which 6 had an amplified c-myc locus. The RNAs were sequentially hybridized with the pRyc7.4 c-myc probe and the p-actin probe. The latter probe was used as a control for the amount of RNA transferred to the membrane. Two breast cancer cell lines, MCF7 and T-47D, were used as positive controls (Fig. 3,  lanes i and j) . The MCF7 cell line showed low levels of amplification (5-fold) of the c-myc locus (data not shown).
AU of the invasive ductal carcinomas bearing an amplified c-myc locus that were examined expressed high levels of the 2.4-kb c-myc RNA (Fig. 3, lanes e-h) A.:.
-I , z... (2) . levels of c-myc RNA was not found in all the tumors studied.
In fact, half the carcinomas containing an apparently normal c-myc gene also showed high levels of c-myc RNA (Fig. 3,  compare lanes c and d with lanes a and b) . Thus, c-myc is highly expressed in 10 of 14(70%7) invasive ductal carcinomas studied. None of the tumors with a rearranged c-myc gene could be examined for RNA expression by blot analysis, due to the low cell/adipose tissue ratio in these tumors or to the effect of prolonged storage at -700C (up to 7 years) on RNA yields.
Alteration of c-myc in Human Invasive Ductal Breast Carcinomas Correlates with the Age of the Patients. We have attempted to correlate cinicopathological and biological data with the presence of amplified or rearranged c-myc in the invasive ductal carcinoma DNAs. As shown in Table 2 , a significant correlation (P < 0.02) was observed between the presence of a genetically altered c-myc in the tumor cells and the age of the patients. Among the 40 patients with an altered c-myc gene, 29 (72.5%) were more than 50 years old at surgery (Table 2) , whereas only 28 of 55 (50.9%) patients presenting a normal c-myc locus were over 50 years of age. Among the first group, 2 carcinomas were from the only 2 male patients that we have studied, 19 were from women who had entered menopause, and 5 were from patients who previously underwent hysterectomy between ages 25 and 45. These 5 patients were all older than 60 years and therefore can be considered postmenopausal. There was no correlation between a genetically altered c-myc locus and the estrogenand progesterone-receptor status, tumor grade, or axillary lymph node metastasis ( (25) . Similarly, the amplification of c-myc and L-myc is frequently observed in highly malignant cell lines derived from variants of smallcell lung carcinomas (12, 26) . A more compelling correlation is provided by two strains of transgenic mice, carrying a mouse mammary tumor virus/c-myc fusion gene (27) . These mice develop a high incidence of mammary adenocarcinomas, suggesting that constitutional deregulation of c-myc contributes to the development of breast carcinomas.
In the present report, we describe a 2-to 15-fold ampliftication of the c-myc gene in 38(32%) of 121 breast carcinomas.
As Rearrangement of c-myc has frequently been observed in tissue culture cell lines derived from B-cell tumors of human and murine origins. In the majority ofthe Burkitt lymphomas, c-myc is translocated from chromosome 8 to the immunoglobulin locus on chromosome 14 (6, 30) . The breakpoint occurs either 5' of c-myc or within its first exon. However, in 15-30% of these tumors, the translocation breakpoint occurs 3' of c-myc and in some cases occurs at a considerable distance from the gene (31, 32) . In these tumors, the translocation partner is either chromosome 2 or 22 and each case involves an immunoglobulin light chain locus (K and X, respectively). In our analysis of 121 breast carcinomas, we found 5 DNAs bearing non-germ-line c-myc-related restriction fragments. In one of them, we identified an apparent rearrangement with a breakpoint very near the 3' end of exon 3. Interpretation of the restriction enzyme analysis is not easily compatible with either the deletion or the insertion of genetic material near c-myc. Instead the data suggest that a reciprocal translocation has occurred. The 5.8-kb HindIII and 6.3-kb Pvu II fragments that react with probe c probably represent a portion of chromosome 8 that has been exchanged with another chromosome. Examination of recombinant clones of this rearranged c-myc gene should give insight into the identity of the translocation partner 'and provide probes to determine whether the other rearranged c-myc genes observed in this study represent similar translocation events.
Amplification or rearrangement of protooncogenes is generally associated with their enhanced expression. Indeed, we found high levels of c-myc RNA in all six invasive ductal carcinomas bearing an amplified c-myc. However, we also observed elevated levels of c-myc expression in four of eight tumors in which the gene appeared unaltered. It is conceivable that more subtle alterations, affecting RNA stability, or rearrangements outside the regions defined by the EcoRI and HindIII sites (31) are responsible for the enhanced levels of c-myc RNA in these tumors. Another possibility is that cellular gene(s) that affect the regulation of c-myc have been altered. Little is known about the factors that normally regulate the expression of c-myc in epithelial cells of the breast. Recent studies (33) of c-myc expression in developing human embryos suggest that the expression ofthis gene is not simply linked to cell proliferation but rather is under cell type-specific and developmental control. Examination of levels of c-myc RNA in frozen tissue sections should provide more information on the possible relationship between enhanced expression and clinicopathological parameters, including stages of tumor development.
Although we have not examined all the known protooncogenes, the frequency of genetic alteration of the c-myc locus is striking. Moreover, the results presented show that the frequency of altered c-myc has a significant correlation (P < 0.02) with patients over 50 years of age at surgery. The women composing this group of patients were either postmenopausal or had an earlier hysterectomy (25 or 30 years of age). In addition, the only two tumors from male patients examined each contained an amplified c-myc. The physiological characteristics 'and/or additional genetic mutations that separate this group of patients from other breast tumor patients remain to be determined. More extensive studies on the genomic integrity and expression of c-myc and other cellular protooncogenes, coupled with more detailed information on the physiological characteristics of the patients and breast tumors, should allow further insight into the genetic alterations that contribute to the development of breast tumors.
